Tumor-Infiltrating CD8+ T Cells Driven by the Immune Checkpoint-Associated Gene IDO1 Are Associated With Cervical Cancer Prognosis

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Nov 15

PMID 34778035

Citations 6

Authors

Shun Zhang

Junhui Wan

Minjie Chen

Desheng Cai

Junlan Xu

Qi Chen

Affiliations

Soon will be listed here.

Abstract

Tumor-infiltrating immune cells, associated with tumor progression, are promising prognostic biomarkers. However, the relationship between levels of gene expression and that of immune cell infiltration in cervical cancer prognosis is unknown. In this study, three cervical cancer gene expression microarrays (GSE6791, GSE63678 and GSE55940) were obtained from the GEO database. The IDO1 gene was identified by differentially expressed gene screening. The gene expression profiles of TCGA and GTEx databases along with comprehensive bioinformatics analysis identified that the IDO1 gene was upregulated in cervical cancer with significant difference in expression at different N stages. In addition, it was also upregulated in HPV16 positive sample. The pan-cancer analysis identified that IDO1 was highly expressed in most cancers. TIMER analysis revealed that the expression of IDO1 in CESC shows positive correlation with CD8 T cells, CD4 T cells, neutrophils, dendritic cells. IDO1 expression showed remarkable positive correlation with all immune cell markers except M1 macrophages. CD8 T cell infiltration GSEA results showed that IDO1 was mainly associated with tumor immune-related signaling pathways.

Citing Articles

IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment.

Wu Z, Wang H, Zheng Z, Lin Y, Bian L, Geng H J Transl Med. 2025; 23(1):275.

PMID: 40045363 PMC: 11884131. DOI: 10.1186/s12967-025-06276-x.

High-throughput non-homogenous 3D polycaprolactone scaffold for cancer cell and cancer-associated fibroblast mini-tumors to evaluate drug treatment response.

Malakpour-Permlid A, Rodriguez M, Untracht G, Andersen P, Oredsson S, Boisen A Toxicol Rep. 2025; 14:101863.

PMID: 39758801 PMC: 11699757. DOI: 10.1016/j.toxrep.2024.101863.

CD8 T cell-based cancer immunotherapy.

Chen Y, Yu D, Qian H, Shi Y, Tao Z J Transl Med. 2024; 22(1):394.

PMID: 38685033 PMC: 11057112. DOI: 10.1186/s12967-024-05134-6.

A novel extrachromosomal circular DNA related genes signature for overall survival prediction in patients with ovarian cancer.

Zhang Y, Dong K, Jia X, Du S, Wang D, Wang L BMC Med Genomics. 2023; 16(1):140.

PMID: 37337170 PMC: 10278296. DOI: 10.1186/s12920-023-01576-x.

CircRNA-Based Cervical Cancer Prognosis Model, Immunological Validation and Drug Prediction.

Guo X, Chen S, Wang S, Zhang H, Yin F, Guo P Curr Oncol. 2022; 29(11):7994-8018.

PMID: 36354693 PMC: 9689098. DOI: 10.3390/curroncol29110633.

References

Munn D, Mellor A . IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016; 37(3):193-207. PMC: 4916957. DOI: 10.1016/j.it.2016.01.002. View

Thomas N, Busam K, From L, Kricker A, Armstrong B, Anton-Culver H . Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013; 31(33):4252-9. PMC: 3821014. DOI: 10.1200/JCO.2013.51.3002. View

Farhood B, Najafi M, Mortezaee K . CD8 cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2018; 234(6):8509-8521. DOI: 10.1002/jcp.27782. View

Seo A, Lee H, Kim E, Kim H, Jang M, Lee H . Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013; 109(10):2705-13. PMC: 3833219. DOI: 10.1038/bjc.2013.634. View

Jung K, LoRusso P, Burris H, Gordon M, Bang Y, Hellmann M . Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clin Cancer Res. 2019; 25(11):3220-3228. PMC: 7980952. DOI: 10.1158/1078-0432.CCR-18-2740. View

Kitamura T, Qian B, Pollard J . Immune cell promotion of metastasis. Nat Rev Immunol. 2015; 15(2):73-86. PMC: 4470277. DOI: 10.1038/nri3789. View

Zou R, Gu R, Yu X, Hu Y, Yu J, Xue X . Characteristics of Infiltrating Immune Cells and a Predictive Immune Model for Cervical Cancer. J Cancer. 2021; 12(12):3501-3514. PMC: 8120169. DOI: 10.7150/jca.55970. View

Liang Y, Lu W, Zhang X, Lu B . Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer. Diagn Pathol. 2018; 13(1):93. PMC: 6260654. DOI: 10.1186/s13000-018-0770-4. View

Azimi F, Scolyer R, Rumcheva P, Moncrieff M, Murali R, McCarthy S . Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012; 30(21):2678-83. DOI: 10.1200/JCO.2011.37.8539. View

10.

Lu M, Li S, Yang H, Morrisey E . Foxp4: a novel member of the Foxp subfamily of winged-helix genes co-expressed with Foxp1 and Foxp2 in pulmonary and gut tissues. Mech Dev. 2003; 119 Suppl 1:S197-202. DOI: 10.1016/s0925-4773(03)00116-3. View

11.

Sheu B, Chang W, Lin H, Chow S, Huang S . Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia. J Obstet Gynaecol Res. 2007; 33(2):103-13. DOI: 10.1111/j.1447-0756.2007.00492.x. View

12.

Duranti S, Pietragalla A, Daniele G, Nero C, Ciccarone F, Scambia G . Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data. Cancers (Basel). 2021; 13(9). PMC: 8123488. DOI: 10.3390/cancers13092089. View

13.

Maliniemi P, Laukkanen K, Vakeva L, Dettmer K, Lipsanen T, Jeskanen L . Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas. Oncoimmunology. 2017; 6(3):e1273310. PMC: 5384345. DOI: 10.1080/2162402X.2016.1273310. View

14.

Kiyozumi Y, Baba Y, Okadome K, Yagi T, Ishimoto T, Iwatsuki M . IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer. Ann Surg. 2019; 269(6):1101-1108. DOI: 10.1097/SLA.0000000000002754. View

15.

Piersma S . Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron. 2011; 4(3):361-75. PMC: 3234326. DOI: 10.1007/s12307-011-0066-7. View

16.

Favre D, Mold J, Hunt P, Kanwar B, Loke P, Seu L . Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010; 2(32):32ra36. PMC: 3034445. DOI: 10.1126/scitranslmed.3000632. View

17.

Pardee K, Green A, Takahashi M, Braff D, Lambert G, Lee J . Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components. Cell. 2016; 165(5):1255-1266. DOI: 10.1016/j.cell.2016.04.059. View

18.

Yentz S, Smith D . Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy. BioDrugs. 2018; 32(4):311-317. DOI: 10.1007/s40259-018-0291-4. View

19.

Schatton T, Scolyer R, Thompson J, Mihm Jr M . Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol. 2013; 1102:287-324. DOI: 10.1007/978-1-62703-727-3_16. View

20.

Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U . Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest. 2015; 125(2):739-51. PMC: 4319435. DOI: 10.1172/JCI74894. View